Record Details

<span style="font-size:11.0pt;font-family: "Times New Roman";mso-fareast-font-family:"Times New Roman";mso-bidi-font-family: Mangal;mso-ansi-language:EN-GB;mso-fareast-language:EN-US;mso-bidi-language: HI" lang="EN-GB">Anti-cholinergic alkaloids as potential therapeutic agents for Alzheimer’s disease: An <i style="mso-bidi-font-style:normal">in silico</i> approach</span>

NOPR - NISCAIR Online Periodicals Repository

View Archive Info
 
 
Field Value
 
Title Anti-cholinergic alkaloids as potential therapeutic agents for Alzheimer’s disease: An in silico approach
 
Creator Naaz, Huma
Singh, Swati
Pandey, Veda P
Singh, Priyanka
Dwivedi, Upendra N
 
Subject Anti-cholinergic
Anti-cholinesterase
Alkaloids
Alzheimer’s disease
Pleiocarpine
Molecular docking
Pleiocarpine
 
Description 120-125
Alzheimer’s disease
(AD), a progressive neurodegenerative disorder with many cognitive and neuropsychiatric
symptoms is biochemically characterized by a
significant decrease in the brain neurotransmitter acetylcholine (ACh).
Plant-derived metabolites, including alkaloids have been reported to possess
neuroprotective properties and are considered to be safe, thus have potential
for developing effective therapeutic molecules for neurological disorders, such
as AD.
Therefore, in the
present study, thirteen plant-derived alkaloids, namely pleiocarpine, kopsinine, pleiocarpamine
(from Pleiocarpa mutica, family: Annonaceae), oliveroline, noroliveroline, liridonine,
isooncodine, polyfothine, darienine (from Polyalthia
longifolia, family:
Apocynaceae) and eburnamine, eburnamonine, eburnamenine and
geissoschizol
(from Hunteria zeylanica, family: Apocynaceae) were
analyzed for their anti-cholinergic action
through docking with acetylcholinesterase (AChE) as
target. Among the alkaloids, pleiocarpine showed
promising anti-cholinergic potential, while its amino derivative showed about
six-fold higher anti-cholinergic potential than pleiocarpine. Pleiocarpine and
its amino derivative were found to be better inhibitors of AChE, as compared to
commonly used drugs tacrine

(brand name: Cognex) and rivastigmine (brand name: Exelon), suggesting development of these molecules as potential therapeutics
in future.


 
Date 2013-04-18T07:30:25Z
2013-04-18T07:30:25Z
2013-04
 
Type Article
 
Identifier 0975-0959 (Online); 0301-1208 (Print)
http://hdl.handle.net/123456789/17097
 
Language en_US
 
Rights CC Attribution-Noncommercial-No Derivative Works 2.5 India
 
Publisher NISCAIR-CSIR, India
 
Source IJBB Vol.50(2) [April 2013]